ARF tumor suppressor protein is a key regulator of the MDM2-p53 signaling axis. ARF interferes with MDM2-mediated ubiquitination and degradation of p53 by sequestering MDM2 in the nucleolus and preventing MDM2-p53 interaction and nuclear export of p53. Moreover, ARF also directly inhibits MDM2 ubiquitin ligase (E3) activity, but the mechanism remains elusive. Here, we apply nuclear magnetic resonance and biochemical analyses to uncover the mechanism of ARF-mediated inhibition of MDM2 E3 activity. We show that MDM2 acidic and zinc finger domains (AD-ZnF) form a weak intramolecular interaction with the RING domain, where the binding site overlaps with the E2-ubiquitin binding surface and thereby partially reduces MDM2 E3 activity. Binding of human N-terminal 32 residues of p14ARF to the acidic domain of MDM2 strengthens the AD-ZnF-RING domain interaction. Furthermore, the N-terminal RxFxV motifs of p14ARF participate directly in the MDM2 RING domain interaction. This bivalent binding mode of p14ARF to MDM2 acidic and RING domains restricts E2-ubiquitin recruitment and massively hinders MDM2 E3 activity. These findings elucidate the mechanism by which ARF inhibits MDM2 E3 activity.

Introduction

The activity of p53 tumor suppressor protein is tightly regulated by MDM2 ubiquitin ligase (E3). Under unstressed, homeostatic conditions, levels of p53 are low because of the E3 activity of MDM2, where MDM2 catalyzes p53 ubiquitination leading to its proteasomal degradation (Kubbutat et al, 1997; Pant & Lozano, 2014). In response to cellular stresses, numerous factors function to uncouple p53 from MDM2 to enable p53 stabilization and activation of its transcriptional activity to restore cellular homeostasis (Hu et al., 2012). In a variety of wild-type p53 cancers, including soft tissues sarcomas, osteosarcomas, and glioblastomas, amplification of the MDM2 gene has been frequently reported; this drastically reduces p53 protein levels, which in turn promotes cancer growth (Momand et al., 1998; Stefanou et al., 1998; Burton et al., 2002; Karni-Schmidt et al., 2016). In contrast, deficiency in MDM2 is lethal because of uncontrolled p53 activation as demonstrated by embryonic lethality in mice lacking the Mdm2 gene (Jones et al., 1995; Montes de Oca Luna et al., 1995). This fine balance between p53 activity and cell fate signifies the importance of precise regulation of MDM2.

MDM2 inhibits p53’s transcriptional activity by directly binding p53 and promoting p53 ubiquitination and subsequent degradation by the proteasome (Momand et al., 1992; Oliner et al., 1993; Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997; Shi & Gu, 2012). The importance of MDM2 E3 activity in p53 regulation is underscored by mouse studies, where expression of catalytically inactive Mdm2 mutants results in embryonic lethality that is rescued by Trp53 deletion (Itahana et al., 2007; Humphton et al., 2021). The core of MDM2 E3 activity resides in its C-terminal RING domain. The RING domain functions by recruiting E2 thioesterified ubiquitin (E2~Ub; ~indicates thioester bond) and priming the E2~Ub thioester bond for nucleophilic attack by the lysine side chain of substrate (Dou et al., 2012; Plechanova et al., 2012). MDM2’s RING domain activity is regulated by dimerization, where MDM2 RING domain homodimerization or heterodimerization with the MDMX RING domain is essential for binding E2~Ub in the active conformation to confer E3 activity (Nomura et al., 2017; Magnusson et al., 2020). Furthermore, phosphorylation of Ser429 after DNA damage directly contributes to stabilization of E2~Ub to enhance MDM2 E3 activity (Magnussen et al., 2020). In addition to the RING domain, MDM2 consists of three other structured domains connected through regions predicted to be unstructured (Fig 1A). This “beads-on-a-string” architecture enables protein–protein interactions and posttranslational modifications (PTMs) to modulate MDM2 E3 activity (Wade et al., 2013; Fährnaeus & Olivares-Illana, 2014). For example, binding of ribosomal proteins by the zinc finger (ZnF) region inhibits MDM2’s activity toward p53 (Lohrum et al., 2003; Zhang et al., 2003; Dai et al., 2004; Dai & Lu, 2004; Jin et al., 2004), and phosphorylation of MDM2 by Chk2, ATM, and CKI promotes MDM2 ubiquitination and degradation (Chen et al., 2005; Perez et al., 2005; Inuzuka et al., 2010).

The ARF tumor suppressor is one of the most extensively studied negative regulators of MDM2 (Sherr, 2006). Human p14ARF and its close homolog, mouse p19ARF, are reported to interact with MDM2’s
Figure 1. MDM2220-334 interacts with the MDM2RING domain.

(A) Schematic showing the domain structure of MDM2. MDM2 harbors an N-terminal p53-binding domain (p53BD), a region containing nuclear localization sequence and nuclear export sequence (NLS/NES), an acidic and zinc finger (AD-ZnF) region, and a C-terminal RING domain. MDM2 constructs used in this study are indicated.

(B) Schematic showing the domain structure of human p14ARF. Sequence alignment of the N-terminal 29 residues in p14ARF and p19ARF with conserved residues highlighted in red and ARF motifs (RxFxV) are indicated below.

(C) SDS-PAGE showing pull-downs of co-expressed GST-MDM2RING and His-GFP-MDM2220-334. Lane 1 contains GST-MDM2RING expressed on its own and purified by glutathione affinity chromatography. Co-expression of GST-MDM2RING and His-GFP-MDM2220-334 was first
acidic domain (AD), leading to stabilization and activation of p53 (Kamijo et al, 1998; Pomerantz et al, 1998; Stott et al, 1998; Zhang et al, 1998). The N-terminal 60 residues share the highest sequence similarity in p14ARF and p19ARF. Studies showed that the N-terminal 29 residues of p14ARF are sufficient for MDM2 binding and p53 activation (Fig 1B) (Kamijo et al, 1998; Midgley et al, 2000; Lohrum et al, 2000a). This sequence is disordered in solution but forms two extended β-strands upon binding to MDM2 AD (Bothner et al, 2001; DiGiarmarino et al, 2001). Importantly, the predicted placement of the β-strands corresponds to the double repetition of the so-called ARF motif, which is a conserved RxFxV sequence present in both homologs of ARF. The mechanism by which the formation of the ARF/MDM2 complex influences p53 has been actively studied over the past two decades. Collectively, studies showed that ARF can localize MDM2 within the nucleus, thereby separating it from p53, prevent MDM2-mediated p53 nuclear export, and inhibit the E3 activity of MDM2 resulting in p53 stabilization (Honda & Yasuda, 1999; Tao & Levine, 1999; Weber et al, 1999; Zhang & Xiong, 1999; Midgley et al, 2000; Lohrum et al, 2000b; Llanos et al, 2001). In vitro characterization of ARF proteins remains challenging as the N-terminal regions encompassing the first 29 residues of ARF proteins are extremely hydrophobic and basic, whereas also reported to undergo oligomerization and precipitation in aqueous buffers (Bothner et al, 2001; Sivakolundu et al, 2008). Furthermore, protein aggregation prediction (http://old.protein.bio.unipd.it/past2/) suggests that the N-terminal 29 residues of ARF proteins have a propensity to form aggregates (Walsh et al, 2014). Thus, it remains difficult to characterize how ARF binding to MDM2 AD could influence MDM2 E3 activity.

A recent study showed that MDM2 could form intramolecular interactions between its AD and RING domains and that this interaction appeared to be enhanced by p14ARF in a pull-down experiment (Cheng et al, 2014). To better understand how p14ARF binding to MDM2 AD could modulate the activity of the RING domain, we focused on the 32 N-terminal residues of p14ARF (N32p14ARF) that is sufficient for MDM2 binding and performed nuclear magnetic resonance (NMR) and biochemical analyses to investigate the interactions between MDM2 AD, MDM2 RING domain, and N32p14ARF. We developed a stable fusion construct containing the N32p14ARF and MDM2 AD-ZnF domains to overcome the challenging behavior of isolated ARF protein. In this study, we show that MDM2 AD-ZnF forms weak interactions with the E2–Ub binding surface of the RING domain to reduce E2–Ub binding affinity and activity. N32p14ARF binding to MDM2 AD-ZnF greatly enhances the interaction with the RING domain and outcompetes E2–Ub to inhibit E3 activity. Moreover, we demonstrate that the N-terminal RxRxV motifs of N32p14ARF are essential for inhibition of MDM2 RING activity. These findings provide insights into how the ARF tumor suppressor protein inhibits the E3 activity of MDM2 and have implications for therapies directed at MDM2 and how the regulation of MDM2 and p53 contribute to oncogenesis.

Results

MDM2 AD-ZnF contacts the E2–Ub binding surface of MDM2 RING domain

A prior study showed that direct fusion of AD (residues 230–260) to the RING domain (residues 410–491) stimulated the catalytic activity of the RING domain (Cheng et al, 2014). Because this fusion construct lacks the region encompassing residues 261–409, how this intramolecular interaction modulates MDM2 activity in the context of native MDM2 sequence remains unclear. To assess interactions between the AD and RING domains, we generated constructs encoding His-GFP–tagged MDM2220–334 containing AD and ZnF regions (GFP–AD–ZnF) and GST–tagged MDM2419–C containing the RING domain (MDM2RING), co-expressed both constructs in Escherichia coli, and performed Ni–NTA affinity pull-down followed by glutathione–senphasor affinity pull-down. The double pull-down experiment revealed the formation of a complex between MDM2 AD–ZnF and RING domains (Fig 1C). To confirm this interaction and to map the AD–ZnF–binding site on the RING domain, we purified 15N–labeled MDM2RING and acquired 1H,15N–HSQC spectra while titrating MDM2220–334 (AD–ZnF). Signals in the 15N–MDM2RING spectra were assigned based on a previous study (Kostic et al, 2006) (Fig S1A). Titration of 15N–MDM2RING with a molar excess of AD–ZnF produced moderate chemical-shift perturbations (CSPs) with several attenuations, suggesting a weak interaction between AD–ZnF and the RING domains (Fig 1D–F). The NMR data allowed us to map the AD–ZnF binding surface on the RING domain (Fig 1G). CSPs for many residues near the RING/E2–Ub interface were above average, including Val258, Ile262, Glu267, Met269, and Ala270, which are involved in binding the hydrophobic region of UBE2D2, and His274, Val277, Cys278, and Glu280, which are involved in stabilizing the donor Ub (Nomura et al, 2017; Magnussen et al, 2020) (Fig 1G and H). In addition, several signals from the Lys666/Ile685 region distal from the E2–Ub binding site were perturbed. To verify that E2–Ub induces CSPs in 15N–MDM2RING, we titrated 15N–MDM2RING with sub-stoichiometric ratios of UBE2D2–Ub and showed that addition of UBE2D2–Ub led to attenuation of many cross-peaks including those of Ile440 and His657 along the E2–Ub binding surface, but not Lys666 or Ile685 (Fig S1B), consistent with the published structure of the MDM2 RING domain bound to UBE2D2–Ub (Magnussen et al, 2020). Together, these findings demonstrate that AD–ZnF binds to the RING domain and shares a binding surface with E2–Ub.
AD-ZnF inhibits E3 ligase activity

Given that AD-ZnF and E2–Ub contact the same surface on the RING domain, we set out to determine how AD-ZnF impacts the E3 activity of MDM2. For this purpose, we compared the E3 activity and E2–Ub binding affinity of MDM2RING and MDM2320-C (containing AD-ZnF and the RING domain). We purified GST-MDM2RING and GST-MDM2320-C for these analyses (Fig 2A). We performed single-turnover lysine discharge assay by monitoring the rate of UBE2D2–Ub discharge to free lysine in the presence of MDM2 variants. By using saturated lysine as the acceptor, UBE2D2–Ub preferentially transfers Ub to free lysine and eliminates contributions from autoubiquitination arising from differences in lysine residue accessibility in the two MDM2 constructs. We found that MDM2320-C displayed reduced activity compared with MDM2RING (Fig 2B and C). We also performed surface plasmon resonance (SPR) analysis to measure the UBE2D2–Ub binding affinity. MDM2RING exhibited higher affinity for UBE2D2–Ub (Kd = 14.5 ± 1.4 μM) compared with that of MDM2320-C (Kd = 57.5 ± 1.6 μM) (Fig 2D). These results support the hypothesis that AD-ZnF restricts E2–Ub binding and thereby reduces the E3 activity of MDM2.

To investigate the roles of AD and ZnF in MDM2RING binding, we generated GFP-MDM2220–288 (GFP-AD) and GFP-MDM2289–334 (GFP-ZnF), where GFP was used to improve the stability of AD and ZnF. We titrated 15N-MDM2RING with molar excess of GFP-AD-ZnF, GFP-AD, or GFP-ZnF. At a 1:2 molar ratio of 15N-MDM2RING:GFP-AD-ZnF, several residues exhibited moderate CSPs with several attenuations (Fig S2A), similar to the titration of 15N-MDM2RING with molar excess of AD-ZnF lacking GFP (Fig 1D). In contrast, at the same molar ratio, GFP-AD produced minimal CSPs, whereas GFP-ZnF had no effect (Figs 2B and C). Next, we assessed the effects of GFP-AD–ZnF, GFP-AD, and GFP-ZnF on MDM2RING-mediated UBE2D2–Ub discharge. Addition of GFP-AD–ZnF in trans reduced MDM2RING activity compared with GFP alone, whereas GFP-AD and GFP-ZnF had no effect (Figs 2E and F and S3). Collectively, these results showed that the combination of AD and ZnF regions are required for binding to the MDM2RING domain to exert the inhibitory effect.

The N-terminus of p14ARF interacts with MDM2 AD

The N-terminal region of p14ARF has been shown to bind to the MDM2 AD and reduce MDM2 in vitro autoubiquitination (Midgley et al, 2000). Given that AD-ZnF interacts with the RING domain, we next assessed how p14ARF binding to the AD could modulate the RING domain activity. We verified the interaction between the N-terminal 32 residues of p14ARF (N32p14ARF) and MDM2 by co-expressing His-GFP-tagged N32p14ARF and GST-tagged MDM2320-C in E. coli and then performing Ni-NTA affinity pull-down followed by glutathione-sepharose affinity pull-down. A complex of His-GFP-N32p14ARF and GST-MDM2320-C was detectable after double-affinity pull-down (Fig 3A). We then compared the E3 activity of the His-GFP-N32p14ARF/GST-MDM2320-C complex and GST-MDM2320-C using a lysine discharge assay and found that N32p14ARF had an inhibitory effect on the E3 activity (Fig 3B and C). To assess how p14ARF interacts with MDM2, it would be ideal to work with N32p14ARF; however, this construct is not expressed in the soluble form in E. coli, and the synthetic peptide does not dissolve in aqueous buffers. Our double-pull-down result suggests that when N32p14ARF is co-expressed with its binding partner, there is a stabilizing effect. With this in mind, we designed a multidomain fusion protein with GFP-tagged N32p14ARF fused to MDM2220–334 at the C-terminus (Fig 3D). The resulting GFP-N32p14ARF–[GGSG]6–MDM2220–334 fusion protein (hereafter referred to as GFP-N32p14ARF–AD-ZnF) was eluted from the gel filtration column at a volume consistent with a monomer (Fig 3E). Furthermore, the [GGSG]6 linker was ranked by two thrombin cleavage sites, allowing GFP-N32p14ARF to be freed from AD-ZnF to verify that the two proteins were still bound when no longer fused (Fig 3D–F). With GFP-AD-ZnF and the GFP-N32p14ARF–AD-ZnF fusion, we proceeded to compare how p14ARF–binding to the AD of MDM2 modulates the AD-ZnF inhibition of the RING domain.

MDM2 AD-ZnF/RING interaction is strengthened by p14ARF

Having shown that AD-ZnF binds MDM2 RING domain and N32p14ARF, we set out to address how E3 activity was affected in the presence of all three components. We titrated the GFP-N32p14ARF–AD-ZnF construct into 15N-MDM2RING and monitored CSPs by 1H,15N-HSQC. At the sub-stoichiometric 1:0.15 molar ratio of 15N-MDM2RING:GFP-N32p14ARF–AD-ZnF, several residues had detectable CSPs, whereas some residues were attenuated (Figs 4A and S4A). There were widespread signal attenuations upon further titration to a stoichiometric molar ratio, indicative of the formation of a larger protein complex leading to enhanced relaxation and line broadening. We mapped the residues with CSPs and attenuated signals obtained at a 1:0.15 molar ratio of 15N-MDM2RING:GFP-N32p14ARF–AD-ZnF onto the structure of the MDM2 RING domain homodimer (Fig 4B). Similar to AD-ZnF, the GFP-N32p14ARF–AD-ZnF fusion affected the E2–Ub binding surface of MDM2 RING domain including above-average CSPs present for Ile440, His457, Lys473, Cys478, and Gin480 (Fig 4A–C). In addition, Asn433 and Glu436 from the 310-helical turn preceding the RING domain involved in donor Ub binding (Magnussen et al, 2020) displayed above-average CSPs. As with AD-ZnF, few CSPs were observed in the Phe462/Asn465 patch distal from the E2–Ub–binding site (Fig 4B). Overlay of 1H,15N-HSQC spectra in the presence of GFP-N32p14ARF–AD-ZnF or GFP-AD-ZnF demonstrates incorporation of N32p14ARF greatly enhances attenuation of the signals indicative of enhanced RING/AD–ZnF interaction (Fig 4D). As the NMR titration experiments were performed with GFP fusions to stabilize N32p14ARF, we verified that GFP alone did not affect signals of 15N-MDM2RING in 1H,15N-HSQC spectra (Fig S4B). To assess whether MDM2RING was still active in this ternary complex and with N32p14ARF, we carried out lysine discharge assays. In this assay, discharge of UBE2D2–Ub by MDM2RING was monitored across increasing concentrations of GFP-AD–ZnF or GFP-N32p14ARF–AD-ZnF. Addition of GFP-AD–ZnF reduced MDM2RING activity compared with GFP alone. In contrast, addition of GFP-N32p14ARF–AD-ZnF further hindered MDM2RING activity compared with GFP-AD–ZnF (Figs 4E and S5).

p14ARF directly binds MDM2 RING to inhibit E3 activity

Thus far, we have shown that N32p14ARF strengthens the MDM2 AD-ZnF-driven inhibition of the RING domain. However, whether this
Figure 2. AD-ZnF of MDM2 inhibits its ligase activity.

(A) SDS–PAGE (left panel) and size exclusion elution profile (right panel) showing the purity of GST-MDM2^{230-C} and GST-MDM2^{RING} proteins. (B) Non-reduced SDS–PAGE showing the discharge of UBE2D2–Ub to L-lysine over time, catalyzed by GST-MDM2^{RING} and GST-MDM2^{230-C}. Asterisks indicate fluorescently labeled Ub. (C) Plot showing the rate of UBE2D2–Ub discharge in (B). Data are from two independent experiments (n = 2). The line represents the mean value. (D) Surface plasmon resonance analysis of UBE2D2–Ub binding to GST-MDM2^{230-C} and GST-MDM2^{RING}. Sensograms are on the left and binding curves on the right. Data are from two independent experiments (n = 2). The equilibrium dissociation constants (K_d) are indicated. Error bar indicates SEM. (E) Plot of UBE2D2–Ub left at the 1-min time point, corresponding to (F). Data are presented as mean value ± SD from three independent experiments (n = 3). (F) Non-reduced SDS–PAGE showing the discharge of UBE2D2–Ub to L-lysine over time, catalyzed by MDM2^{RING} in the presence of 50 μM of GFP, GFP-AD-ZnF, GFP-AD, or GFP-ZnF. Asterisks indicate fluorescently labeled Ub.
results from direct contact between p14ARF and the RING domain or
whether p14ARF-bound AD indirectly modulates the AD-ZnF/RING
interaction remains ambiguous. To investigate whether p14ARF
interacts directly with MDM2 RING domain, we co-expressed His-
GFP-tagged N32p14ARF and GST-tagged MDM2350-C in
E. coli and performed Ni-NTA affinity pull-down followed by glutathione-
sepharose affinity pull-down. GST-MDM2 230-C was pulled down
along with His-GFP-N32p14ARF after double-affinity pull-down
(Figs 3A and 5A). In contrast, His-GFP-N32p14ARF pulled down GST-
MDM2350-C on the first Ni-NTA affinity pull-down, but in the second
glutathione-sepharose affinity pull-down, only GST-MDM2350-C was
present (Fig 5A). We noticed that the His-GFP-N32p14ARF pull-down
product was considerably less abundant after the first Ni-NTA
affinity pull-down when co-expressed with GST-MDM2350-C, sug-
gestind that MDM2 lacking the AD might not be able to make a stable
complex with N32p14ARF. Nonetheless, the results suggested that
His-GFP-N32p14ARF exhibits weak affinity for MDM2350-C. Although
the synthetic N32p14ARF peptide is soluble in DMSO, addition of
N32p14ARF peptide to MDM2RING in the aqueous buffer caused
precipitation. Thus, to further validate whether p14ARF directly
contacts MDM2RING, we generated a fusion construct, N32p14ARF-
MDM2350-C, in which N32p14ARF was linked to a variant of the MDM2
RING domain that included ~80 residues of the native sequence
before the RING domain to allow for flexibility and solubility of
N32p14ARF (Fig 5B). Discharge of UBE2D2~Ub was reduced with the
N32p14ARF-MDM2350-C fusion, suggesting that N32p14ARF has an
inhibitory effect on the MDM2 RING domain (Fig 5C). In addition,
binding of UBE2D2–Ub to the N32p14ARF-MDM2350-C fusion was
abolished (Fig 5D).

Next, we focused on the role of the “ARF motifs” in N32p14ARF in
the inhibition of the MDM2 RING domain. Both p14ARF and mouse
p19ARF contain two conserved RxFxV motifs within the first and
second N-terminal β-strands (Fig 1B). We mutated six key residues
in the RxFxV motifs to alanine (R3A,F5A,V7A,R21A,F23A,V25A; 6Ala;Fig
Figure 3. N32p14ARF interacts with MDM2220-334.
(A) SDS–PAGE showing pull-downs of co-expressed GST-MDM2230-C and His-GFP-N32p14ARF. Lane 1 contains GST-MDM2230-C expressed on its own and purified by glutathione affinity chromatography. Co-expression of GST-MDM2230-C and His-GFP-N32p14ARF was first purified by N72 affinity chromatography (eluant shown in lane 2) and subsequently purified by glutathione affinity chromatography (eluant shown in lane 3). (B) Non-reduced SDS–PAGE showing the discharge of UBE2D2–Ub to L-lysine over time, catalyzed by GST-MDM2230-C and the GST-MDM2230-C/GFP-N32p14ARF complex. Asterisks indicate fluorescently labeled Ub. (C) Plot showing the rate of UBE2D2–Ub discharge in (B). Data are from three independent experiments (n = 3). The line represents the mean value. (D) Schematic showing the design of the GFP-N32p14ARF-AD-ZnF construct, with the glycine and serine linker [GGSG], flanked by two thrombin cleavage sequences. (E) Overlayed size exclusion elution profiles of GFP-
N32p14ARF-AD-ZnF alone (green line) and treated with thrombin (magenta line) in comparison to MDM2 AD-ZnF (black line). (F) SDS–PAGE showing the eluted peak fraction corresponding to untreated GFP-N32p14ARF-AD-ZnF (lane 1) and thrombin-treated GFP-N32p14ARF-AD-ZnF (lane 2) in (E). Asterisks indicate trace contaminants.
Figure 4. N-terminus of p14ARF strengthens the MDM2RING/AD-ZnF inhibitory interaction.

(A) Residue-specific CSPs (black) and signal attenuations (gray) of $^{15}$N-MDM2RING after addition of GFP-N32p14ARF-AD-ZnF at a 1:0.15 M ratio. The average CSP is indicated by the black dashed line.

(B) Residues with above-average CSPs or signal attenuation from (A) (orange) are mapped onto the green MDM2RING protomer in the structure of the MDM2RING homodimer (PDB ID: 6SQO) with the other MDM2RING protomer in gray. Cartoon representation with transparent surface view of MDM2RING homodimer structure is shown.

(C) UBE2D2–Ub (UBE2D2 in blue and Ub in wheat, shown as a cartoon view) is shown in complex with MDM2RING homodimer (PDB ID: 6SQO, shown as a surface view). Colored and oriented as in the right panel in (B).

(D) Overlay of $^1$H,$^1$N HSQC spectra of $^{15}$N-MDM2RING (black), in the presence of GFP-AD-ZnF (red), and

p14ARF and MDM2 AD inhibit RING activity Kowalczyk et al. https://doi.org/10.26508/lsa.202201472 vol 5 | no 12 | e202201472 7 of 13
5B) in the N32p14ARF-MDM2RING fusion and showed that this N32p14ARF6Ala-MDM2RING fusion had enhanced activity in the UBE2D2-Ub discharge assay and improved UBE2D2-Ub binding affinity compared with the N32p14ARF-MDM2RING fusion (Fig 5C and D). The N32p14ARF6Ala-MDM2RING fusion was slightly less active and bound UBE2D2-Ub marginally weaker compared with that of MDM2RING, suggesting that other residues in N32p14ARF likely contribute to binding of the RING domain. These data demonstrate that N32p14ARF directly binds and inhibits the E3 activity of the MDM2 RING domain.

Discussion

Uncovering how MDM2’s E3 activity is modulated is critical for understanding how MDM2 regulates p53 levels. The combined NMR and biochemical assays presented in this study demonstrate that the RING domain of MDM2 forms an intramolecular interaction with the AD-ZnF region and recognizes E2~Ub through a conserved surface. Our data support the hypothesis that the AD-ZnF region of MDM2 directly binds the RING domain and restricts the access of E2~Ub, leading to a reduction in E3 activity. NMR and activity assays revealed that the observed AD-ZnF/RING interaction is weaker than the RING/E2~Ub interaction. This suggests that under normal conditions, MDM2 RING domain could still access E2~Ub to exert its E3 activity despite having a slightly reduced E2~Ub binding affinity. Cheng et al (2014) previously reported that the AD could stimulate RING domain activity (Cheng et al, 2014). These differences in the observed effects on RING domain activity may arise from directly fusing the AD to the RING domain in their study, whereas our construct contains the native sequence (MDM2RING) that encompasses the AD-ZnF region connected to the RING domain by a flexible linker. Indeed, our data showed that the combination of AD and ZnF regions are required for optimal AD-ZnF/RING interactions to occlude E2~Ub binding.

Stress signals, such as DNA damage, have been shown to affect MDM2 PTMs, as well as its interactions with binding partners. Therefore, either PTMs or binding partners could potentially modulate the intramolecular interaction between MDM2 AD-ZnF and the RING domain, thereby increasing or abolishing inhibition of MDM2 E3 activity. p14ARF has been shown to bind MDM2 AD, but how it inhibits MDM2 E3 activity remains elusive. We showed that N32p14ARF binding to the AD of MDM2 hindered the activity of the C-terminal RING domain. Furthermore, the N32p14ARF/MDM2 AD-ZnF fusion complex greatly reduced MDM2 E3 activity by blocking the E2~Ub binding surface of the RING domain. The extent of CSPs and signal attenuations in 15N-MDM2RING spectra and additional CSPs in the 310-helical region in the presence of GFP-N32p14ARF-AD-ZnF compared with GFP-AD-ZnF hinted that N32p14ARF not only strengthens the AD-ZnF and RING domain interaction but also directly binds to the RING domain. Indeed, when N32p14ARF was fused to the N-terminus of MDM2 RING domain, the conserved ARF motifs were essential for inhibiting MDM2 E3 activity. Our data suggest a model whereby the weak AD-ZnF interaction with the RING domain perturbs E2~Ub binding and allows MDM2 to be “primed” for inhibition (Fig 6). The binding of N32p14ARF to MDM2 AD enhances MDM2 AD-ZnF interaction with the RING domain and enables N32p14ARF to directly engage the RING domain. MDM2 AD-ZnF and the RING domains are separated a long unstructured linker. Therefore, it is likely that N32p14ARF binding would induce a global conformational change in the AD-ZnF and RING domains, restraining the MDM2 RING domain in an autoinhibited conformation and thereby restricting MDM2-mediated ubiquitination.

As documented in over three decades of studies, numerous effectors have been reported to bind to MDM2 (Fährnaeus & Olivares-Illana, 2014). For example, the AD-ZnF region is required for MDM2 interaction with ribosomal proteins, which in turn leads to activation of p53 (Liu et al, 2016). It remains unknown how other effectors of MDM2 exert their inhibitory effect, but it is plausible that they could take advantage of MDM2’s “primed” state and inhibit MDM2 through a similar mechanism as ARF. In contrast, when MDM2 binds to p53, MDM2 AD is reported to contact p53 to facilitate MDM2-mediated p53 ubiquitination (Kawai et al, 2003; Meulmeester et al, 2003; Yu et al, 2006). How MDM2 AD facilitates p53 ubiquitination is not clear. It seems likely that MDM2 AD could bind to and orient p53 for optimal ubiquitination by E2~Ub bound to the MDM2 RING domain. At the same time, MDM2 AD binding to p53 would perturb MDM2 AD-ZnF/RING interaction and relieve the inhibition of MDM2 E3 activity to allow MDM2-mediated p53 ubiquitination. p53 has been shown to form a ternary complex with MDM2 and ARF (Kamijo et al, 1998; Stott et al, 1998; Zhang et al, 1998). Although a detailed binding mechanism of the ternary complex is unknown, it seems plausible that ARF would bind the well-established MDM2 AD and thereby uncouples MDM2 AD-p53 contact to perturb MDM2-mediated p53 ubiquitination. Furthermore, based on our findings, we posit that the ARF could engage in bivalent interaction with MDM2 AD and RING domains to restrain MDM2 E3 activity in the ternary complex, resulting in p53 stabilization. Future structural characterization of MDM2/p53/ARF complexes will be required to unravel the detailed binding mechanism.

p14ARF and p19ARF proteins remain challenging to study in vitro because of the amyloid-like feature of their N-terminal sequences (Bothner et al, 2001). The methodology employed to generate stable and monomeric fusions of N32p14ARF and MDM2 AD-ZnF could be useful for future studies in characterizing this complex alone and in the complex with the RING domain at atomic resolution. Structural insight into the binding mode could pave the way for the development of MDM2 RING domain inhibitors that will have paramount clinical importance. Most of the therapeutic strategies focus on the MDM2/p53 interaction by targeting MDM2’s N-terminal p53 binding domain with nutlin derivatives or synthetic peptides (Skalniak et al, 2019). Our related work has shown that targeting the RING domain might be a suitable alternative to reactivate p53 (Nomura et al, 2017; Humpton et al, 2021). Therefore, this study will guide future work on MDM2 RING and expands on a promising mechanism to inhibit the E3 activity of MDM2 through the RING domain.

GFP-N32p14ARF-AD-ZnF (cyan) with both at a 1:0.5 molar ratio. (E) Non-reduced SDS-PAGE showing the discharge of UBE2D2-Ub to L-lysine over time, catalyzed by MDM2RING alone or in the presence of increasing concentrations of GFP-AD-ZnF or GFP-N32p14ARF-AD-ZnF. Asterisks indicate fluorescently labeled Ub.
Materials and Methods

Generation of constructs

All DNA constructs were generated using standard PCR techniques with the Q5 High-Fidelity kit (NEB) and verified by automated sequencing. GST-tagged constructs were cloned into a modified pGEX-4T-1 vector (Cytiva), which provides an N-terminal GST sequence followed by a TEV cleavage site. His-tagged constructs were cloned into modified pRSFDuet-1 (Merck Millipore), which provides an N-terminal 6xHis or 12xHis tag, followed by TEV cleavage sequence. MDM2RING and MDM2RINGAD-sequence was expressed with 6xHis tag using a stable variant of MDM2RING harboring G443T (Magnussen & Huang, 2021). All constructs containing GFP were expressed with a 12xHis tag. The N32p14ARF6Ala-MDM2RING construct was generated by site-directed mutagenesis using PfuUltra High-Fidelity DNA Polymerase (Agilent) and verified by DNA sequencing. The GFP-N32p14ARF-MDM2RING sequence was shown, where the RxFxV motif is highlighted in red. Non-reduced SDS–PAGE showing the discharge of UBE2D2–Ub from the GST-MDM2RING by GST-N32p14ARF-MDM2RING. Asterisks indicate fluorescently labeled Ub. Surface plasmon resonance analysis of UBE2D2–Ub binding to GST-MDM2RING, GST-N32p14ARF-MDM2RING, and GST-N32p14ARF6Ala-MDM2RING. Sensograms are on the left and binding curves on the right. Data are from two independent experiments (n = 2). The equilibrium dissociation constants (K_d) are indicated. N.m. indicates not measurable. Error bar indicates SEM.

Figure 5. N-terminus of p14ARF directly targets MDM2RING domain. (A) Western blot showing pull-downs of co-expressed GST-MDM2RING (left panel) or GST-MDM2RINGAD (right panel) and His-GFP-N32p14ARF detected with anti-GST (red) or anti-GFP (green) antibodies. Lane 1 contains GST-MDM2 variants expressed on their own and purified by glutathione affinity chromatography. Lanes 2 and 3 are the eluants from the first (Ni-NTA affinity purification) and second (glutathione affinity purification) steps, respectively. (B) Schematic showing the design of the MDM2RING and N32p14ARF-MDM2RING constructs. N32p14ARF and N32p14ARF6Ala sequences are shown, where the RxFxV motif is highlighted in red. (C) Non-reduced SDS–PAGE showing the discharge of UBE2D2–Ub to L-lysine over time, catalyzed by GST-MDM2RING, GST-N32p14ARF-MDM2RING, and GST-N32p14ARF6Ala-MDM2RING. Asterisks indicate fluorescently labeled Ub. (D) Surface plasmon resonance analysis of UBE2D2–Ub binding to GST-MDM2RING, GST-N32p14ARF-MDM2RING, and GST-N32p14ARF6Ala-MDM2RING. Sensograms are on the left and binding curves on the right. Data are from two independent experiments (n = 2). The equilibrium dissociation constants (K_d) are indicated. N.m. indicates not measurable. Error bar indicates SEM.
with 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 20°C overnight. 15N-MDM2RING was obtained from M9 medium based on a previously published protocol (Studier, 2005). In summary, 300 ml of Luria Bertani medium was inoculated from a single colony and grown overnight at 37°C. Cells were pelleted, washed in M9 medium, and resuspended to a final volume of 60 ml. Cells were then transferred to 6 liters of M9 medium containing 15NH4Cl (1 g/l) and grown at 37°C until reaching an OD600 of 0.6–0.7 and induced with 0.2 mM IPTG at 16°C for 20 h.

**Protein purification**

Bacterial cells were centrifuged and lysed with a microfluidizer. Cells expressing His-tagged constructs were resuspended in buffer containing 25 mM Tris–HCl (pH 7.6), 400 mM NaCl, 1 mM Tris(2-carboxyethyl)phosphine (TCEP), 5% (vol/vol) glycerol, and imidazole (25 mM for 6xHis tag protein and 50 mM for 12xHis tag protein). Cells expressing GST-tagged constructs were resuspended in buffer containing 50 mM Tris–HCl (pH 7.6), 400 mM NaCl, 1 mM TCEP, and 5% (vol/vol) glycerol. The same buffers were used for washing during the affinity chromatography steps. All proteins, except for 15N-MDM2RING, were purified into a final buffer containing 25 mM Tris–HCl (pH 7.6), 400 mM NaCl, and 1 mM TCEP. The buffer used for elution of GST-tagged proteins contained 50 mM Tris–HCl (pH 8.0), 400 mM NaCl, 1 mM TCEP, 5% (vol/vol) glycerol, and 10 mM glutathione (GSH), whereas buffer used for elution of His-tagged proteins contained 25 mM Tris–HCl (pH 7.6), 400 mM NaCl, 1 mM TCEP, 5% (vol/vol) glycerol, and 200 mM imidazole. GST-tagged MDM2 variants were purified by glutathione affinity chromatography, followed by HiLoad 26/600 Superose6 chromatography. GST-N32p14ARF-MDM2350-C variants were purified by glutathione affinity chromatography, and buffer exchanged into the final buffer. MDM2220-334 was purified by glutathione affinity chromatography, followed by cleavage from the resin with TEV protease at 4°C overnight. Cleaved MDM2 was collected and purified by HiLoad 26/600 Superose6 chromatography. His-GFP-MDM2220-334, His-GFP-MDM2250-288, His-GFP-MDM2230-334, and His-GFP-N32p14ARF-AD-ZnF were purified by Ni-NTA affinity chromatography, followed by HiLoad 26/600 Superose6 chromatography. MDM2RING was purified by Ni-NTA affinity chromatography, followed by buffer exchange on a HiPrep 26/10 Desalting column. The His tag was removed by incubation with TEV protease at 4°C overnight, followed by Ni-NTA pass back. Cleaved MDM2RING was purified by HiLoad 26/600 Superdex 75 chromatography. 15N-MDM2RING was purified by Ni-NTA affinity chromatography without removal of the 6xHis-tag, followed by HiLoad 26/600 Superdex 75 chromatography into buffer containing 20 mM sodium phosphate, (pH 7.0), 300 mM NaCl, and 1 mM TCEP. Protein concentration was determined by Bio-Rad protein assay. His-GFP-MDM2230-334, His-GFP-MDM2250-288, His-GFP-MDM2230-334, and His-GFP-N32p14ARF-AD-ZnF were determined by using molar extinction coefficient at 280 nm. MDM2 protein concentration was determined based on the molecular weight of a monomer.

**In vitro pull-down experiments**

GST-MDM2RING and 12xHis-GFP-MDM2220-334 (Fig 1C), GST-MDM2230-C and 12xHis-GFP-N32p14ARF (Figs 3A and 5A), or GST-MDM2230-C and 12xHis-GFP-N32p14ARF (Fig 5A) were co-expressed in E. coli. Six liters of cells were grown according to the aforementioned recombinant protein expression. Cells were centrifuged and lysed by sonication. Clarified lysates were applied onto 400 μl of Ni-NTA resin, washed, and eluted with the aforementioned Ni-NTA affinity purification buffers. Total protein was quantified by Bio-Rad protein assay, and 5 μg of the eluted fraction was analyzed by SDS–PAGE and detected with InstantBlue staining (Figs 1C and 3A), anti-GST (Cytiva 27-4577-01; 1:1,000 dilution), and IRDye 800CW donkey anti-goat IgG (LI-COR Biosciences; 1:15,000 dilution) antibodies or anti-GFP (Santa Cruz 81045; 1:1,000 dilution) and IRDye 800CW goat anti-mouse IgG (LI-COR Biosciences; 1:15,000 dilution) antibodies (Fig 5A).

**SPR assays**

All experiments were done at 25°C using a Biacore T200, equilibrated in running buffer containing 25 mM Tris–HCl (pH 7.6), 300 mM...
NaCl, 0.5 mM TCEP, and 0.005% (vol/vol) Tween-20. CM-5 chips with anti-GST-nanobodies (GST VH4; Chromotech) were used to couple GST-MDM2 variants to a level of ~500 response units, with GST as a control. UBE2D2^SSVR was used as an analyte, was purified as described previously (Buetow et al., 2015) and serially diluted in running buffer. Binding between GST-MDM2 variants and UBE2D2–Ub was measured in duplicate, across seven concentrations of UBE2D2–Ub, starting at 100 μM and decreasing in a twofold manner. Data shown are the difference between SPR signal recorded for GST-MDM2 variants and GST alone. The data were analyzed by steady-state affinity using Biacore T200 evaluation software (GE Healthcare) and plotted in Prism8 (GraphPad).

**Single-turnover lysine discharge assays**

Lysine discharge assays were performed as described previously (Buetow et al., 2015). Arabidopsis thaliana UBA1, UBE2D2^SSVR, and IRDye 800CW maleimide-labeled GGSC-Ub were prepared as described previously (Magnussen et al., 2020). Briefly, 2 μM of UBE2D2^SSVR was charged with 4 μM of maleimide-labeled Ub in the presence of 0.2 μM A. thaliana UBA1 in buffer containing 50 mM Tris–HCl (pH 7.6), 50 mM NaCl, 5 mM MgCl₂, and 20 mM ATP for 20 min at room temperature and stopped by addition of 25 mM EDTA for 5 min. Lysine (final concentration of 250 mM for Fig 2B; 50 mM for Figs 2F, 3B, 4E, and 5C) and the indicated MDM2 variant or MDM2/p14ARF complex (final concentration: 100 nM for Fig 2B; 200 nM for Figs 2F, 3B, 4E, and 5C) were then added to initiate the reaction. Because of the nanomolar concentration of MDM2 variants used in the assay, it was not possible to visualize MDM2 variant bands by Coomassie staining. To standardize the MDM2 variant concentration used in the assay, we determined the MDM2 variants protein concentration and then loaded equimolar quantities on SDS–PAGE to ensure similar loading of MDM2 variants (Fig S6) before dilution for use in the assay. For Figs 2F, 3B, 4E, and 5C) were then added to initiate the reaction. Reactions were quenched with SDS loading buffer at the indicated times, analyzed by SDS–PAGE and visualized using a LI-COR Odyssey CX1 scanner. Images were prepared using Image Studio software (LI-COR Biosciences). The reactions in Figs 2B and 3B were performed in duplicate and triplicate, respectively. Image Studio software (LI-COR Biosciences) and ImageJ were used to analyze the scanned gels and quantify the intensities of the bands. The plots were generated using Prism8 (GraphPad).

**Size exclusion analysis**

Size exclusion analyses in Fig 2A were done using the 10/300 Superdex 200 chromatography column. 500 μL of protein (~200–500 μg) was applied onto the column pre-equilibrated in buffer containing 25 mM Tris–HCl (pH 7.6), 400 mM NaCl, and 1 mM TCEP. Data were presented using wavelength at 215 nm and normalized for comparison. To demonstrate that N32p14ARF interacts with MDM2^320–334 in the GFP-N32p14ARF-AD-ZnF (Fig 3E), 300 μg of GFP-N32p14ARF-AD-ZnF was incubated in either buffer alone or in the presence of 3 μg of thrombin at 4°C overnight before loading onto the 10/300 Superdex 200 column.

**Solution NMR experiments**

All NMR experiments were acquired using a Bruker Avance III 600-MHz spectrometer equipped with a cryogenic triple resonance inverse probe. Before titration, each sample was exchanged into NMR buffer (20 mM sodium phosphate, 300 mM NaCl, 0.5 mM TCEP, 5.0% [vol/vol] D₂O, pH 7.0). Experiments were carried out at 298 K, and ¹H–¹⁵N HSQC spectra were recorded with 16 scans using 64 complex points with a sweep width of 36 parts per million (ppm) in the ¹⁵N dimension. All spectra were processed with 256 points in the indirect dimension using Bruker TopSpin version 3.5 patch level 7 and analyzed using CARA (http://cara.nmr.ch/) and CCPnmr (Skinner et al., 2016). CSPs were calculated following:

\[
\text{CSP} = \left(\frac{\delta_{HA} - \delta_{HB}}{5}\right)^2 + \left(\frac{\delta_{HA} - \delta_{HB}}{5}\right)^2
\]

For a given residue in state A or B, δ_A and δ_B are the differences in proton and nitrogen chemical shifts, respectively.

**Data Availability**

The data supporting the findings of this study are within the paper and its supplemental information.

**Supplementary Information**

Supplementary information is available at https://doi.org/10.26508/lsa.202201472.

**Acknowledgements**

We would like to thank the Core Services and Advanced Technologies at the Cancer Research UK Beatson Institute (CS96/A17196 and A31287), Catherine Winchester, and Lori Buetow for critical reading of the manuscript. This work was supported by Beatson Institute core funding from Cancer Research UK (A17196 and A31287), Cancer Research UK funding to DT Huang (A23278/A647849), and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no 647849).

**Author Contributions**

DKowalczyk: conceptualization, data curation, formal analysis, investigation, methodology, and writing—original draft, review, and editing.

MA Nakasone: data curation, formal analysis, investigation, methodology, and writing—original draft, review, and editing.

BSmith: data curation, formal analysis, and writing—review and editing.
DT Huang: conceptualization, formal analysis, supervision, funding acquisition, investigation, project administration, and writing—original draft, review, and editing.

Conflict of Interest Statement

DT Huang is a consultant for Triana Biomedicines. The other authors declare no competing interests.

References

Bothner B, Lewis WS, DiGiambattista EL, Weber JD, Bothner SJ, Kriwacki RW (2001) Defining the molecular basis of Arf and Mdm2 interactions. J Mol Biol 314: 263–277. doi:10.1006/jmbi.2001.1510

Buetow L, Gabrielsen M, Anthony NG, Dou H, Patel A, Atkenhead H, Sibbet GJ, Smith BC, Huang DT (2015) Activation of a primed RING E3–ubiquitin complex by non-covalent ubiquitin. Mol Cell 58: 297–310. doi:10.1016/j.molcel.2015.02.017

Burton EC, Lamborn KR, Forsyth P, Scott J, O’Campo J, Uyehara-Lock J, Prados M, Burger M, Passe S, Uhnh J, et al (2002) Aberrant p53, mdm2, and MDMX in glioblastomas with p53 damage. Mol Cell 10: 539–542. doi:10.1016/S1097-2765(02)00472-3

Cheng Q, Song T, Chen L, Chen J (2014) Autoactivation of the MDM2 E3 ligase by intramolecular interaction. Mol Cell Biol 34: 2800–2810. doi:10.1128/mcb.00246-14

Dai MS, Lu H (2004) Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 279: 44467–44482. doi:10.1074/jbc.m403722200

Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H (2004) Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 24: 7654–7668. doi:10.1128/mcb.24.17.7654-7668.2004

DiGiambattista EL, Filipovic I, Weber JD, Bothner B, Kriwacki RW (2001) Solution structure of the p53 regulatory domain of the p19ARF tumor suppressor protein. Biochemistry 40: 2379–2386. doi:10.1021/bi010210i

Dou H, Buetow L, Sibbet GJ, Cameron K, Huang DT (2012) BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer. Nat Struct Mol Biol 19: 876–883. doi:10.1038/nsmb.2379

Fährus R, Oliveses-Illana V (2014) Mdm2’s social network. Oncogene 33: 4335–4376. doi:10.1038/onc.2013.410

Haupert Y, Maya R, Kazaa A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299. doi:10.1038/387296a0

Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25–27. doi:10.1016/s0014-5793(97)01480-4

Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18: 22–27. doi:10.1093/emboj/18.1.22

Hu W, Peng J, Levine AE (2012) The regulation of multiple p53 stress responses is mediated through MDM2. Genes Cancer 3: 199–208. doi:10.1177/194769191245734

Humphston TJ, Nomura K, Weber J, Magnussen HM, Hock KA, Nixon C, Dhayade S, Stevenson D, Huang DT, Strathdee D, et al (2021) Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice. Genes Dev 35: 117–132. doi:10.1101/2312–2323.

Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, Wan L, Ang X, Mock C, Yin H, et al (2010) Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCFβ-TRC ubiquitin ligase. Cancer Cell 18: 147–159. doi:10.1016/j.ccr.2010.06.015

Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS, Bhat KP, Godfrey VL, Evan GI, Zhang Y (2007) Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12: 355–366. doi:10.1016/j.ccr.2007.09.007

Jin A, Itahana K, O’Keefe K, Zhang Y (2004) Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 24: 7669–7680. doi:10.1128/mcb.24.17.7669-7680.2004

Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206–208. doi:10.1038/378206a0

Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 95: 8292–8297. doi:10.1073/pnas.95.14.8292

Karni-Schmidt O, Lokshin M, Prives C (2016) The roles of MDM2 and MDMX in cancer. Annu Rev Pathol 11: 617–644. doi:10.1146/annurev-pathol-021414-040349

Kawai H, Wiederschain D, Yuan ZM (2003) Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23: 4939–4947. doi:10.1128/mcb.23.14.4939-4947.2003

Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE (2006) Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol 363: 433–450. doi:10.1016/j.jmb.2006.08.027

Kubbutat MHG, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299–303. doi:10.1038/387299a0

Liu Y, Deisenroth C, Zhang Y (2016) RP-MDM2–p53 pathway: Linking ribosomal biogenesis and tumor surveillance. Trends Cancer 2: 191–204. doi:10.1016/j.trecan.2016.03.002

Llanos S, Clark PA, Rowe J, Peters G (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 3: 445–452. doi:10.1038/35074506

Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH (2000a) Contribution of two independent MDM2-binding domains in p14ARF to p53 stabilization. Cell 10: 539–542. doi:10.1016/S0092-8674(00)00472-3

Lohrum MAE, Ashcroft M, Kubbutat MHG, Vousden KH (2000b) Identification of a cryptic nuclear-localization signal in MDM2. Nat Cell Biol 2: 179–181. doi:10.1038/35040457

Lohrum MA, Ludwig RL, Kubbutat MH, Hanion M, Vousden KH (2003) Regulation of MDM2 activity by the ribosomal protein L11. Cancer Cell 3: 577–587. doi:10.1016/S1535-6108(03)00134-x

Magnussen HM, Ahmed SF, Sibbet GJ, Hristova VA, Nomura K, Hock AK, Archibald LJ, Jameson AG, Fushman D, Vouwen KH, et al (2020) Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain. Nat Commun 11: 204. doi:10.1038/s41467-020-15783-y

Magnussen HM, Huang DT (2021) Identification of a catalytic active but non-aggregating MDM2 RING domain variant. J Mol Biol 433: 166807. doi:10.1016/j.jmb.2021.166807

Meulemeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH, Jochensm AG (2003) Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23: 4929–4938. doi:10.1128/mcb.23.14.4929-4938.2003

Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19: 2312–2323. doi:10.1038/sj.onc.1203593
Nomand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. *Nucleic Acids Res* 26: 3453–3459. doi:10.1093/nar/26.15.3453

Nomand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell* 69: 1237–1245. doi:10.1016/0092-8674(92)90644-r

Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. *Nature* 378: 203–206. doi:10.1038/378203a0

Nomura K, Klejnot M, Kowalczyk D, Hock AK, Sibbet GJ, Vousden KH, Huang DT (2017) Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity. *Nat Struct Mol Biol* 24: 578–587. doi:10.1038/nsmb.3414

Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor gene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. *Cell* 73: 362–373. doi:10.1016/0092-8674(93)90644-r

Pant V, Lozano G (2014) Limiting the power of p53 through the ubiquitin proteasome pathway. *Genes Dev* 28: 1739–1751. doi:10.1101/gad.247452.114

Pereg Y, Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M, Biton S, Teunisse AFAS, Lehmann WD, Jochemsen AG, et al (2005) Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. *Proc Natl Acad Sci U S A* 102: 5056–5061. doi:10.1073/pnas.0408595102

Plechanova A, Jaffray EG, Tatham MH, Naismith JH, Hay RT (2012) Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. *Nature* 489: 115–120. doi:10.1038/nature11376

Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Belanger M, Stainier D, Fischer E, Fialkow PJ, et al (2006) The central region of HDM2 provides a second binding site for p53. *Nat Cell Biol* 8: 240–248. doi:10.1038/ncll0354

Shi D, Gu W (2012) Dual roles of MDM2 in the regulation of p53: Ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. *Genes Cancer* 3: 240–248. doi:10.1177/1947619123455999

Sivakolundu SG, Nourse A, Moshiaci S, Bothner B, Ashley C, Satumba J, Lahti J, Kriwacki RW (2008) Intrinsically unstructured domains of Arf and Hdm2 form bimolecular oligomeric structures in vitro and in vivo. *J Mol Biol* 384: 240–254. doi:10.1016/j.jmb.2008.09.019

Skalniak L, Surmiak E, Holak TA (2019) A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018). *Expert Opin Ther Pat* 29: 151–170. doi:10.1080/13543776.2019.1582645

Skinner SP, Fogh RH, Boucher W, Ragan TJ, Mureddu LG, Vuister GW (2016) CcpNmr AnalysisAssign: A flexible platform for integrated NMR analysis. *J Biomat. NMR* 66: 111–124. doi:10.1007/s10858-016-0060-y

Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, et al (1998) The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. *EMBO J* 17: 5001–5014. doi:10.1093/emboj/17.17.5001

Stefanou DG, Nonni AV, Agnantis NJ, Athanassiadou SE, Briassoulis E, Pavlidis N (1998) p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study. *Anticancer Res* 18: 4673–4681.

Studier FW (2005) Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif* 41: 207–234. doi:10.1016/j.pep.2005.01.016

Tao W, Levine AJ (1999) P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. *Proc Natl Acad Sci U S A* 96: 6937–6941. doi:10.1073/pnas.96.12.6937

Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. *Nat Rev Cancer* 13: 83–96. doi:10.1038/nrc3430

Walsh I, Seno F, Tosatto SC, Trovato A (2014) PASTA 2.0: An improved server for protein aggregation prediction. *Nucleic Acids Res* 42: W301–W307. doi:10.1093/nar/gku399

Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D (1999) Nucleolar Arf sequesters Mdm2 and activates p53. *Nat Cell Biol* 1: 20–26. doi:10.1038/8991

Yu GW, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez MR, Fersht AR (2006) The central region of HDM2 provides a second binding site for p53. *Proc Natl Acad Sci U S A* 103: 1227–1232. doi:10.1073/pnas.0510343103

Zhang Y, Xiong Y (1999) Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and neutralizes MDM2’s inhibition of p53. *Cell* 92: 713–723. doi:10.1016/s0092-8674(00)81400-2